P53 tumour suppressor gene and germ cell neoplasia

APMIS

Volumn 106, Issue 1, 1998, Pages 85-89

  Lutzker, Stuart G ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Chemosensitivity; Germ cell tumour; p53

Indexed keywords

DNA; PROTEIN P53; TRANSCRIPTION FACTOR;

CHEMOSENSITIVITY; CONFERENCE PAPER; DNA DAMAGE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GERM CELL TUMOR; HUMAN; NONHUMAN; PRIORITY JOURNAL; TERATOCARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0031939282     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1998.tb01323.x     Document Type: Conference Paper

References (43)

1. Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., Lukas, J., Rejthar, A., Kovarik, J., Midgley, C., Gannon, J., & Lane, D.: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene, 6: 1699-1703, 1991.
2. Bartkova, J., Bartek, J., Lukas, J., Voijesek, B., Staskova, Z., Rejthar, A., Kovarik, J., Midgley, C. A., & Lane, D. P.: P53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int. J. Cancer. 49: 196-202, 1991.
3. Canman, C., Gilmer, T., Coutts, S., & Kastan, M.: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes & Dev., 9: 600-611, 1995.
4. Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.: Crystal structure of a p53 tumour suppressor-DNA complex: Understanding tumourigenic mutations. Science, 265: 346-355, 1994.
5. Chresta, C. M., Masters, J. R. W., & Hickman, J. A.: Hypersensitivity of human testicular tumours to etoposide-induced apoptosis is associated with functional p53 and a high bax:bcl-2 ratio. Cancer Res., 56: 1834-1841, 1996.
6. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Brennan, M. F., Marechal. V., Chen, J., & Levine, A. J.: Molecular abnormalities of mdm-2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54: 794-799, 1994.
7. Debbas, M., & White, E.: Wild-type p53 mediates apoptosis by E1A which is inhibited by E1B. Genes & Develop., 7: 546-554, 1993.
8. Guillou, L., Estreicher, A., Chaubert, P., Hurlimann, J., Kurt, A., Mettez, G., Iggo, R., Gray, A., Jichlinski, P., Leisinger, H., & Benhattar, J.: Germ cell tumours of the testis overexpress wild-type p53. Am. J. Pathol. 149: 1221-1228, 1996.
9. Harvey, M., McArther, M., Montgomery, C., Bradley, A., & Donehower, L.: Genetic background alters the spectrum of tumours that develop in p53-deficient mice. PASEB, 7: 938-943, 1993a.
10. Harvey, M., Sands, A., Weiss, R., Hegi, M., Wiseman, R., Pantazis, P., Giovanella, B., Tainsky, M., Bradley, A., & Donehower, L.: In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene, 8: 2457-2567, 1993b.
11. Heimdal, K., Lothe, R. A., Lystad, S., Holm, R., Fossa, S. D., & Börresen, A. L.: No germline TP3 mutations detected in familial and bilateral testicular cancers. Genes Chromosom. Cancer, 6: 92-97, 1993.
12. Kemp, C., Wheldon, T., & Balmain, A.: P53-deficient mice are extremely susceptible to radiation-induced tumourigenesis. Nature Genetics, 8: 66-69, 1994.
13. Kuczyk, M., Serth, J., Bokemeyer, C., Jonassen, J., Machtens, S., Wermer, M., & Jonas, U.: Alterations of the p53 tumour suppressor gene in carcinoma in situ of the testis. Cancer, 78: 1958-1966, 1996.
14. Levine, A. J.: P53, the cellular gate keeper for growth and division. Cell, 88: 323-331, 1997.
15. Lewis, D., Sesterhenn, I., McCarthy, W., & Moul, J.: Immunohistochemical expression of p53 tumour suppressor gene protein in adult germ cell testis tumours: Clinical correlation in stage I disease. J. Urol., 152: 418-423, 1994.
16. Liu, F., Es, C., Chen, J., Shih, R., Yang, C., & Shih, A.: Overexpression or mutation of the p53 tumour suppressor gene does not occur in malignant ovarian germ cell tumours. Cancer, 76: 291-295, 1995.
17. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., & Tlsty, T.: Altered cell cycle arrest and gene amplification potential accompany loss of Wild-type p53. Cell, 70: 923-935, 1992.
18. Lowe, S., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D., Housman, D., & Jacks, T.: p53 status and the efficiency of cancer therapy in vivo. Science, 266: 807-810, 1994.
19. Lu, H., & Levine, A. J.: Human TAF-31 is a transcriptional coactivation of the p53 protein. Proc. Natl. Acad. Sci. USA, 92: 5154-5158, 1995.
20. Lutzker, S., & Levine, A.: Apoptosis and cancer chemotherapy. Cancer Treat Res., 87: 345-356, 1996a.
21. Lutzker, S., & Levine, A. J.: A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Medicine, 2: 804-810, 1996b.
22. Marx, L., Dietl, J., & Horny, H.-P.: Overexpression or mutation of the p53 tumour suppressor gene does not occur in malignant ovarian germ cell tumours. Cancer, 78: 179-180, 1996.
23. Masters, J., Osborne, E., Walker, M., & Parris, C.: Hyper-sensitivity of human testis-tumour cell lines to chemotherapeutic drugs. Int. J. Cancer, 346: 340-346, 1993.
24. Moll, U. M., Riou, G., & Levine, A. J.: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA. 89: 7262-7266, 1992.
25. Moll, U., LaQuaglia, M., Benard, J., & Riou, G.: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated but not differentiated neuroblastomas. Proc. Natl. Acad. Sci. USA, 92: 4407-4411, 1995.
26. Nicol, C., Harrison, M., Laposa, R., Gimelshtein, I., & Wells, P.: A teratologic suppressor role of p53 in benzo-a-pyrene-treated transgenic p53-deficient mice. Nature Genet, 10: 181-187, 1995.
27. Noguchi, T., & Stevens, L.: Primordial germ cell proliferation in fetal testis in mouse strains with high and low incidence of congenital testicular teratomas. J. Natl. Cancer Inst., 69: 907-913, 1982.
28. Norimura, T., Nomoto, S., Katsuki, M., Gondo, Y., & Kondo, S.: P53-dependent apoptosis suppresses radiation-induced teratogenesis. Nature Med, 2: 577-580, 1996.
29. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D., & Vogelstein, B.: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358: 80-83, 1992.
30. Parris, C., Arlett, C., Lehmann, A., Green, M., & Masters, J.: Differential sensitivities to gamma radiation of human bladder and testicular cell lines. Int. J. Radiat. Biol. & Relat. Stud. Phys. Chem. & Med., 53: 599-608, 1988.
31. Peng, H. Q., Hogg, D., Malkin, D., Bailey, D., Gallie, B. L., Bulbul, M., Jewett, M., Buchanan, J. & Goss, P. E.: Mutations of the p53 gene do not occur in testis cancer. Cancer Res., 53: 3574-3578, 1993.
32. Pennica, D., Goeddel, D. V., Hayflick, J. S., Reich, N. C., Anderson, C. W., & Levine, A. J.: The amino acid sequence of murine p53 determined from a cDNA clone. Virology, 134: 477-483, 1984.
33. Reich, N. C., Oren, M., & Levine, A. J.: Two distinct mechanisms regulate the levels of a cellular tumour antigen, p53. Mol. Cell. Biol., 3: 2143-2150, 1983.
34. Riou, G., Barrois, M., Prost, S., Terrier, M., Theodore, C., & Levine, A. J.: The p53 and mdm-2 genes in human testicular germ-cell tumours. Molecular Carcinogenesis, 12: 124-131, 1995.
35. Rotter, V., Schwartz, D., Almon, E., Goldfinger, N., Kapon, A., Meshorer, A., Donehower, L., & Levine, A.: Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc. Natl. Acad. Sci. USA, 90: 9075-9079, 1993.
36. Sah, V., Attardi, L., Mulligan, G . Williams, B , Bronson, R., & Jacks, T.: A subset of p53-deficient embryos exhibit exencephaly. Nature Genet, 10: 175-179, 1995.
37. Schenkman, N., Sesterhenn, I., Washington, L., Tong, Y. A., Weghorst, C., Buzard, G., Srivastava, S., & Moul, J.: Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumours. J. Urology, 154: 617-621, 1995.
38. Schmid, P., Lorenz, A., Hameister, H., & Montenarh, M.: Expression of p53 during mouse embryogenesis. Development, 113: 857-865, 1991.
39. Stevens, L.: Spontaneous and experimentally induced testicular teratomas in mice. Cell Differ. 15: 69-74, 1984.
40. Tesch, H., Furba, B., Casper, J., Lyons, J., Bartram, C., Schmoll, H., & Bronson, D.: Cellular oncogenes in human teratocarcinoma cell lines. Int. J. Androl., 13: 377-388, 1990.
41. Thut, C., Chen, J., Klemm, R., & Tjian, R.: p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science, 267: 100-104, 1995.
42. Wang, Y., Reed, M., Wang, P., Stenger, J., Mayr, G., Anderson, M., Schwedes, J., & Tegtmeyer, P.: P53 domains: identification and characterization of two autonomous DNA-binding regions. Genes & Develop., 7: 2575-2586, 1993.
43. Wei, Y. D., Jiafu, Z., Xi, Q. S., Yongjiang, M., Xiulong, Z., Daizong, L., & Jianren, G.: P53 gene mutations in Chinese testicular seminoma. J. Urol., 150: 884-886, 1993.